18 January 2023 ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas
16 December 2022 ORYZON awarded EU grant to further explore the role of iadademstat in oncological immunotherapy approaches
12 December 2022 ORYZON presents final data from Phase IIa ALICE trial in unfit AML patients with first-line treatment of iadademstat and azacitidine in oral presentation at ASH-2022
9 November 2022 ORYZON announces FDA clearance of IND to initiate a collaborative Phase II basket study with iadademstat in R/R patients with Neuroendocrine carcinomas (NECs)
7 November 2022 ORYZON announces oral data presentation at the upcoming 64th American Society of Hematology annual conference